South Korea’s MFDS approved Curocell’s Rimqarto (anbal-cel) as the first homegrown CAR T-cell therapy for patients with advanced diffuse large B-cell lymphoma. The approval, announced April 29, gives the country a domestic CAR T option after years of regulatory and manufacturing buildout. Rimqarto is based on anbalcabtagene autoleucel, expanding the availability of CAR T approaches for eligible relapsed or refractory populations. The milestone reflects MFDS’s willingness to clear novel, locally developed cell therapies. For industry observers, the approval also highlights South Korea’s increasing capacity in advanced therapies and may set expectations for future submissions as local sponsors scale production and clinical evidence.